GlassScriptPhysician profile
Jeffrey S Jump
NPI 1467462150
$4,998.18
in general payments reported to CMS, 2019-2025
34 companies · $843 in 2025
The $843 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $530 · 2020: $306 · 2021: $1,515 · 2022: $434 · 2023: $835 · 2024: $535 · 2025: $843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,820 · Education: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,819.99 |
| Education | $392.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,111.15 | 2020-2021 | |
| Astellas Pharma US INC | $590.02 | 2023-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $518.82 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $477.93 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $258.95 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $232.58 | 2019-2025 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $227.73 | 2019-2025 | Farxiga |
| Pfizer INC. | $181.26 | 2021-2025 | |
| Exact Sciences Corporation | $120.44 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $110.84 | 2019-2024 | Mounjaro, Jardiance |
| Otsuka America Pharmaceutical, INC. | $108.46 | 2023-2024 | Nuedexta, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $103.58 | 2019-2022 | |
| Axsome Therapeutics, INC. | $101.98 | 2025 | Auvelity |
| Amgen INC. | $101.76 | 2019-2023 | Otezla, Repatha |
| Abbott Laboratories | $92.34 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ancora Heart, INC. | $84.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $82.20 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $59.01 | 2024-2025 | Gvoke Hypopen |
| Allergan, INC. | $52.61 | 2020-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.06 | 2024-2025 | Caplyta |
| Lundbeck LLC | $44.70 | 2024-2025 | Rexulti |
| Inspire Medical Systems, INC. | $44.04 | 2025 | Inspire |
| Antares Pharma, INC. | $33.89 | 2022-2024 | Xyosted |
| Merck Sharp & Dohme LLC | $30.17 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.14 | 2020-2021 | |
| Radius Health, INC. | $20.54 | 2019 | |
| Novartis Pharmaceuticals Corporation | $20.07 | 2020 | |
| Seqirus USA INC | $19.45 | 2022 | |
| Azurity Pharmaceuticals, INC. | $19.18 | 2023 | Adthyza |
| Therapeuticsmd, INC. | $15.85 | 2019 | |
| Vyera Pharmaceuticals, LLC | $14.95 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.82 | 2019 | |
| Rare Disease Therapeutics, INC. | $13.17 | 2021 | |
| Boston Scientific Corporation | $12.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Jump listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.